45 results on '"Kfoury, Abdallah G."'
Search Results
2. Contributors
- Author
-
Akhtar, Masood, primary, Almasry, Ibrahim O., additional, Ambrose, Jayaseelan, additional, Auger, William R., additional, Austin, Wendy J., additional, Badhwar, Nitish, additional, Banker, Rajesh, additional, Baram, Daniel, additional, Bates, Eric R., additional, Becker, Richard C., additional, Biolo, Andreia, additional, Brown, David L., additional, Calhoun, David A., additional, Cammarano, William B., additional, Carlson, Mark D., additional, Chalaby, Marc, additional, Chatterjee, Kanu, additional, Cheitlin, Melvin D., additional, Chou, Tony M., additional, Clark, Richard F., additional, Cody, Robert J., additional, Colucci, Wilson S., additional, Daubert, Melissa A., additional, Dauerman, Harold L., additional, DeMott, Megan, additional, Dendi, Raghuveer, additional, Edep, Martin E., additional, Ellis, Stephen G., additional, Ewy, Gordon A., additional, Fedullo, Peter F., additional, Fisher, Patrick W., additional, Foster, Elyse, additional, Gaasch, William H., additional, Gallagher, Christopher J., additional, Gibson, C. Michael, additional, Gilligan, Timothy, additional, Givertz, Michael M., additional, Gogo, Prospero, additional, Goldschlager, Nora, additional, Greenberg, Barry H., additional, Gregg, David, additional, Gruberg, Luis, additional, Gubernikoff, George, additional, Hammock, John, additional, Hoffman, Maureane, additional, Hutchison, Stuart J., additional, Jeremias, Allen, additional, Jorde, Ulrich P., additional, Josephson, Mark E., additional, Jugdutt, Bodh I., additional, Karmpaliotis, Dimitri, additional, Katz, Jason N., additional, Kfoury, Abdallah G., additional, Kleiman, Neal S., additional, Kort, Smadar, additional, Kosmidou, Ioanna, additional, Krishnamani, Rajan, additional, Leder, David M., additional, Little, William C., additional, Mackall, Judith A., additional, Man, Jonathan P., additional, Mani, Anil J., additional, Mathews, Robin, additional, McNulty, Edward, additional, Menon, Dileep, additional, Meyer, Guy, additional, Meyer, Theo E., additional, Minokadeh, Anushirvan, additional, Mitchell, Robert, additional, Mortada, M. Eyman, additional, Naka, Yoshifumi, additional, Nguyen, Michael C., additional, de Oliveira, Eduardo I., additional, Oparil, Suzanne, additional, Parikh, Puja, additional, Patel, Nehal D., additional, Peters, Jay I., additional, Pimenta, Eduardo, additional, Pinto, Duane S., additional, Poovathor, Shaji, additional, Pride, Yuri B., additional, Rabbani, LeRoy E., additional, Raffin, Thomas, additional, Rasmusson, Brad Y., additional, Renlund, Dale G., additional, Richman, Paul, additional, Sayer, Gabriel, additional, Shabetai, Ralph, additional, Selwyn, Andrew Peter, additional, Skopicki, Hal A., additional, Smith, Martin, additional, Sobel, Burton E., additional, Spittell, Peter C., additional, Steinhubl, Steven R., additional, Sullivan, Kristina R., additional, Tschabrunn, Cory M., additional, Tung, Roderick, additional, Tymchak, Wayne J., additional, Vasu, Sujethra, additional, Wadhwa, Nand K., additional, Wagner, Peter D., additional, Wannenburg, Thomas, additional, Williams, Saralyn R., additional, Weiner, Shepard D., additional, Wiener-Kronish, Jeanine P., additional, Wilson, William C., additional, Win, Htut K., additional, Young, Michael, additional, Zevin, Shoshana, additional, Ziada, Khaled M., additional, and Zimetbaum, Peter, additional
- Published
- 2010
- Full Text
- View/download PDF
3. Post-transplant outcome in patients bridged to transplant with temporary mechanical circulatory support devices.
- Author
-
Yin MY, Wever-Pinzon O, Mehra MR, Selzman CH, Toll AE, Cherikh WS, Nativi-Nicolau J, Fang JC, Kfoury AG, Gilbert EM, Kemeyou L, McKellar SH, Koliopoulou A, Vaduganathan M, Drakos SG, and Stehlik J
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Retrospective Studies, Time Factors, Treatment Outcome, Extracorporeal Membrane Oxygenation, Heart Transplantation, Heart-Assist Devices
- Abstract
Background: The new heart allocation system in the United States prioritizes patients supported by temporary mechanical circulatory support (TMCS) devices over those with uncomplicated durable continuous-flow left ventricular assist devices (CF-LVADs), which may increase the number of patients bridged to transplant with TMCS. Limited data are available in guiding post-transplant outcomes with various TMCS devices. We sought to describe post-transplant outcome and identify clinical variables associated with post-transplant outcome in patients bridged to transplant with TMCS., Methods: Using data from the International Society for Heart and Lung Transplantation Thoracic Transplant Registry, we included subjects who underwent transplantation between 2005 and 2016 with known use of mechanical circulatory support. Pre-transplant recipient, donor, and transplant-specific variables were abstracted. The primary outcome was patient survival at 1-year post-transplant. Outcomes of patients bridged to transplant with TMCS were compared with those of patients bridged with CF-LVADs. Cox regression analyses were performed to identify clinical variables associated with the outcomes., Results: There were 6,528 patients bridged to transplant with the following types of mechanical circulatory support: durable CF-LVADs (n = 6,206), extracorporeal membrane oxygenation (ECMO, n = 134), percutaneous temporary CF-LVADs (n = 75), surgically implanted temporary CF-LVADs (n = 38) or surgically implanted temporary BiVAD (n = 75). Bridging with ECMO (hazard ratio 3.79, 95% confidence interval [CI] 2.69-5.34, p < 0.001) or percutaneous temporary CF-LVADs (hazard ratio 1.83, 95% CI 1.09-3.08, p = 0.02) was independently associated with higher risk of mortality. Additional risk factors included older donor age, female/male donor-recipient match, older recipient age, higher recipient body mass index, higher recipient creatinine, and prolonged ischemic time., Conclusions: This analysis of a large international cohort of patients bridged to transplant with mechanical circulatory support identified ECMO and percutaneous temporary CF-LVADs as predictors of mortality after transplant, along with additional donor and recipient clinical characteristics. These findings may provide guidance to clinicians in decisions on mechanical circulatory support device selection, transplant eligibility, and timing of transplant., (Copyright © 2019 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
4. Early immune biomarkers and intermediate-term outcomes after heart transplantation: Results of Clinical Trials in Organ Transplantation-18.
- Author
-
Stehlik J, Armstrong B, Baran DA, Bridges ND, Chandraker A, Gordon R, De Marco T, Givertz MM, Heroux A, Iklé D, Hunt J, Kfoury AG, Madsen JC, Morrison Y, Feller E, Pinney S, Tripathi S, Heeger PS, and Starling RC
- Subjects
- Adult, Enzyme-Linked Immunosorbent Assay, Female, Follow-Up Studies, Gene Expression Profiling, HLA Antigens immunology, Humans, Immune System, Male, Middle Aged, Myosins immunology, Neovascularization, Pathologic, Proportional Hazards Models, Prospective Studies, Retrospective Studies, Risk, T-Lymphocytes immunology, Treatment Outcome, Vascular Endothelial Growth Factor A blood, Vascular Endothelial Growth Factor C blood, Vimentin immunology, Biomarkers metabolism, Heart Failure metabolism, Heart Failure surgery, Heart Transplantation
- Abstract
Clinical Trials in Organ Transplantation-18 (CTOT-18) is a follow-up analysis of the 200-subject multicenter heart transplant CTOT-05 cohort. CTOT-18 aimed to identify clinical, epidemiologic, and biologic markers associated with adverse clinical events past 1 year posttransplantation. We examined various candidate biomarkers including serum antibodies, angiogenic proteins, blood gene expression profiles, and T cell alloreactivity. The composite endpoint (CE) included death, retransplantation, coronary stent, myocardial infarction, and cardiac allograft vasculopathy. The mean follow-up was 4.5 ± SD 1.1 years. Subjects with serum anti-cardiac myosin (CM) antibody detected at transplantation and at 12 months had a higher risk of meeting the CE compared to those without anti-CM antibody (hazard ratio [HR] = 2.9, P = .046). Plasma VEGF-A and VEGF-C levels pretransplant were associated with CE (odds ratio [OR] = 13.24, P = .029; and OR = 0.13, P = .037, respectively). Early intravascular ultrasound findings or other candidate biomarkers were not associated with the study outcomes. In conclusion, anti-CM antibody and plasma levels of VEGF-A and VEGF-C were associated with an increased risk of adverse events. Although this multicenter report supports further evaluation of the mechanisms through which anti-CM antibody and plasma angiogenesis proteins lead to allograft injury, we could not identify additional markers of adverse events or potential novel therapeutic targets., (© 2018 The American Society of Transplantation and the American Society of Transplant Surgeons.)
- Published
- 2019
- Full Text
- View/download PDF
5. Regional myocardial structural characteristics in ischemic and non-ischemic cardiomyopathy: Left ventricle versus right and apex versus base.
- Author
-
Diakos NA, Passi S, Taleb I, Kfoury AG, and Drakos SG
- Subjects
- Atrial Appendage, Cardiomyopathies pathology, Female, Humans, Male, Middle Aged, Prospective Studies, Heart Ventricles pathology, Myocardial Ischemia pathology, Myocardium pathology
- Published
- 2018
- Full Text
- View/download PDF
6. Association of recipient age and causes of heart transplant mortality: Implications for personalization of post-transplant management-An analysis of the International Society for Heart and Lung Transplantation Registry.
- Author
-
Wever-Pinzon O, Edwards LB, Taylor DO, Kfoury AG, Drakos SG, Selzman CH, Fang JC, Lund LH, and Stehlik J
- Subjects
- Adolescent, Adult, Age Factors, Aged, Female, Graft Rejection etiology, Heart Failure complications, Heart Transplantation adverse effects, Humans, Male, Middle Aged, Postoperative Complications etiology, Retrospective Studies, Risk Factors, Young Adult, Graft Rejection mortality, Heart Failure mortality, Heart Failure surgery, Heart Transplantation mortality, Postoperative Complications mortality, Registries
- Abstract
Background: Survival beyond 1 year after heart transplantation has remained without significant improvement for the last 2 decades. A more individualized approach to post-transplant care could result in a reduction of long-term mortality. Although recipient age has been associated with an increased incidence of certain post-transplant morbidities, its effect on cause-specific mortality has not been established., Methods: We analyzed overall and cause-specific mortality of heart transplant recipients registered in the International Society for Heart and Lung Transplantation Registry between 1995 and 2011. Patients were grouped by recipient age: 18 to 29, 30 to 39, 40 to 49, 50 to 59, 60 to 69, and ≥ 70 years. Multivariable regression models were used to examine the association between recipient age and leading causes of post-transplant mortality. We also compared immunosuppression (IS) use among the different recipient age groups., Results: There were 52,995 recipients (78% male; median age [5th, 95th percentile]: 54 [27, 66] years). Survival through 10 years after transplant was lower in heart transplant recipients in the 2 more advanced age groups: 49% for 60 to 69 years and 36% for ≥ 70 years (p < 0.01 for pairwise comparisons with remaining groups). The risk of death caused by acute rejection (hazard ratio [HR], 4.11; p < 0.01), cardiac allograft vasculopathy (HR, 2.85; p < 0.01), and graft failure (HR, 2.29; p < 0.01) was highest in the youngest recipients (18-29 years) compared with the reference group (50-59 years). However, the risk of death caused by infection (HR, 2.10; p < 0.01) and malignancy (HR, 2.23; p < 0.01) was highest in older recipients (≥ 70 years). Similarly, the risk of death caused by renal failure was lower in younger recipients than in the reference group (HR, 0.53; p < 0.01 for 18-49 years vs 50-59 years). The use of induction IS was similar among the different recipient age groups, and differences in maintenance IS were not clinically important., Conclusions: Causes of death in this large cohort of heart transplant recipients varied significantly with recipient age at the time of transplant, with cause-specific mortality profiles suggesting a possible effect of inadequate IS in younger recipients and over-IS in older recipients. Thus, a more personalized approach, possibly including different IS strategies according to recipient age, might result in improved post-transplant survival., (Published by Elsevier Inc.)
- Published
- 2017
- Full Text
- View/download PDF
7. Immunologic effects of continuous-flow left ventricular assist devices before and after heart transplant.
- Author
-
Ko BS, Drakos S, Kfoury AG, Hurst D, Stoddard GJ, Willis CA, Delgado JC, Hammond EH, Gilbert EM, Alharethi R, Revelo MP, Nativi-Nicolau J, Reid BB, McKellar SH, Wever-Pinzon O, Miller DV, Eckels DD, Fang JC, Selzman CH, and Stehlik J
- Subjects
- Female, Graft Rejection, Heart Failure, Heart-Assist Devices, Humans, Isoantibodies, Male, Middle Aged, Heart Transplantation
- Abstract
Background: Immune allosensitization can be triggered by continuous-flow left ventricular assist devices (CF LVAD). However, the effect of this type of allosensitization on post-transplant outcomes remains controversial. This study examined the post-transplant course in a contemporary cohort of patients undergoing transplantation with and without LVAD bridging., Methods: We included consecutive patients who were considered for cardiac transplant from 2006 to 2015. Serum alloantibodies were detected with single-antigen beads on the Luminex platform (One Lambda Inc., Canoga Park, CA). Allosensitization was defined as calculated panel reactive antibody (cPRA) > 10%. cPRA was determined at multiple times. LVAD-associated allosensitization was defined as development of cPRA > 10% in patients with cPRA ≤ 10% before LVAD implantation. Post-transplant outcomes of interest were acute cellular rejection (ACR), antibody-mediated rejection (AMR), and survival., Results: Allosensitization status was evaluated in 268 patients (20% female). Mean age was 52 ± 12 years, and 132 (49.3%) received CF LVADs. After LVAD implant, 30 patients (23%) became newly sensitized, and the level of sensitization appeared to diminish in many of these patients while awaiting transplant. During the study period, 225 of 268 patients underwent transplant, and 43 did not. A CF LVAD was used to bridge 50% of the transplant recipients. Compared with patients without new sensitization or those already sensitized at baseline, the patients with LVAD-associated sensitization had a higher risk of ACR (p = 0.049) and higher risk of AMR (p = 0.018) but a similar intermediate-term post-transplant survival. The patients who did not receive a transplant had higher level of allosensitization, with a baseline cPRA of 20% vs 6% in those who received an allograft and a high risk (40%) of death during follow-up., Conclusions: New allosensitization takes place in > 20% of patents supported with CF LVADs. Among patients who undergo transplant, this results in a higher risk of ACR and AMR, but survival remains favorable, likely due to the efficacy of current management after transplant. However, mortality in sensitized patients who do not reach transplant remains high, and new approaches are necessary to meet the needs of this group of patients., (Published by Elsevier Inc.)
- Published
- 2016
- Full Text
- View/download PDF
8. Myocardial Structural and Functional Response After Long-Term Mechanical Unloading With Continuous Flow Left Ventricular Assist Device: Axial Versus Centrifugal Flow.
- Author
-
Al-Sarie M, Rauf A, Kfoury AG, Catino A, Wever-Pinzon J, Bonios M, Horne BD, Diakos NA, Wever-Pinzon O, McKellar SH, Kelkhoff A, McCreath L, Fang J, Stehlik J, Selzman CH, and Drakos SG
- Subjects
- Adult, Aged, Echocardiography, Female, Heart Failure diagnostic imaging, Heart Failure physiopathology, Hemodynamics, Humans, Male, Middle Aged, Myocardium, Prospective Studies, Stroke Volume, Heart Failure therapy, Heart-Assist Devices
- Abstract
Objectives: The aim of this study was to assess the impact of continuous-flow left ventricular assist device (LVAD) type-axial flow (AX) versus centrifugal flow (CR)-on myocardial structural and functional response following mechanical unloading., Background: The use of continuous-flow LVADs is increasing steadily as a therapeutic option for patients with end-stage heart failure who are not responsive to medical therapy. Whether the type of mechanical unloading influences the myocardial response is yet to be determined., Methods: A total of 133 consecutive patients with end-stage heart failure implanted with continuous-flow LVADs (AX, n = 107 [HeartMate II Thoratec Corporation, Pleasanton, California]; CR, n = 26 [HeartWare, HeartWare International, Framingham, Massachusetts]) were prospectively studied. Echocardiograms were obtained pre-LVAD implantation and then serially at 1, 2, 3, 4, 6, 9, and 12 months post-implantation., Results: The 2 pump types led to similar degrees of mechanical unloading as assessed by invasive hemodynamic status and frequency of aortic valve opening. Myocardial structural and functional parameters showed significant improvement post-LVAD in both AX and CR groups. Left ventricular ejection fraction increased significantly from a mean of 18% to 28% and 26% post-LVAD in the AX and CR groups, respectively. Left ventricular end-systolic volume index and left ventricular end-diastolic volume index decreased significantly as early as 30 days post-implantation in the 2 groups. The degree of myocardial structural or functional response between patients in the AX or CR groups appeared to be comparable., Conclusions: Long-term mechanical unloading induced by AX and CR LVADs, while operating within their routine clinical range, seems to exert comparable effects on myocardial structural and functional parameters., (Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
9. Mixed cellular and antibody-mediated rejection in heart transplantation: In-depth pathologic and clinical observations.
- Author
-
Kfoury AG, Miller DV, Snow GL, Afshar K, Stehlik J, Drakos SG, Budge D, Fang JC, Revelo MP, Alharethi RA, Gilbert EM, Caine WT, McKellar S, Molina KM, and Hammond MEH
- Subjects
- Adolescent, Adult, Aged, Child, Child, Preschool, Female, Graft Rejection diagnosis, Graft Rejection pathology, Humans, Infant, Male, Middle Aged, Retrospective Studies, Young Adult, Antibodies immunology, Graft Rejection immunology, Heart Transplantation, Transplantation Immunology
- Abstract
Background: Little is known about mixed cellular and antibody-mediated rejection (MR) in heart transplantation. It remains unclear whether cardiac MR has distinctive pathologic and clinical features beyond those of simultaneous cellular rejection (CR) and antibody-mediated rejection (AMR). In this study we systematically explore the pathologic and clinical characteristics of MR in heart transplantation., Methods: The UTAH Cardiac Transplant Program database was queried for transplant recipients who survived long enough to have at least one endomyocardial biopsy (EMB) between 1985 and 2014. Only EMBs with both CR and AMR scores documented were included. In addition to detailed pathologic analyses, we also examined the incidence and prevalence of MR, the likelihood to transition from and to MR, and mortality associated with MR., Results: Patients (n = 1,207) with a total of 28,484 EMBs met the study inclusion criteria. The overall prevalence of MR was 7.8% and it was nearly twice as frequent within the first year post-transplant. Mild MR was by far the most common occurrence and was typically preceded by an immune active state. When CR increased in severity, AMR tended to follow, but the reverse was not true. On pathology, individual features of CR and AMR were more easily separated in cases of mild MR, whereas they substantially overlapped in more severe cases. MR was associated with a significant cardiovascular death risk that was incremental with severity., Conclusions: MR is not common, usually occurs early after transplant, and is associated with worse outcomes. MR reflects a complex interplay between cellular and humoral processes, which varies with rejection severity., (Copyright © 2016 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
10. ISHLT pathology antibody mediated rejection score correlates with increased risk of cardiovascular mortality: A retrospective validation analysis.
- Author
-
Hammond MEH, Revelo MP, Miller DV, Snow GL, Budge D, Stehlik J, Molina KM, Selzman CH, Drakos SG, Rami A A, Nativi-Nicolau JN, Reid BB, and Kfoury AG
- Subjects
- Adolescent, Adult, Aged, Cardiovascular Diseases etiology, Child, Child, Preschool, Female, Graft Rejection complications, Humans, Infant, Male, Middle Aged, Postoperative Complications etiology, Retrospective Studies, Risk Assessment, Young Adult, Antibodies immunology, Cardiovascular Diseases mortality, Graft Rejection immunology, Heart-Lung Transplantation, Postoperative Complications mortality
- Abstract
Background: Antibody-mediated rejection (AMR) in cardiac transplant recipients is a serious form of rejection with adverse patient outcomes. The International Society of Heart and Lung Transplantation (ISHLT) has published a consensus schema for the pathologic diagnosis of various grades of antibody-mediated rejection (pathology antibody-mediated rejection [pAMR]). We sought to determine whether the ISHLT pAMR grading schema correlates with patient outcomes., Methods: Using our database, which contains a semi-quantitative scoring of all pathologic descriptors of pAMR, we retrospectively used these descriptors to convert the previous AMR categories to the current ISHLT pAMR categories. Cox proportional hazard models were fit with cardiovascular (CV) death or retransplant as the outcome. The pAMR value was included as a categorical variable, and cellular rejection (CR) values were included in a separate model., Results: There were 13,812 biopsies from 1,014 patients analyzed. The pAMR grades of pAMR1h, pAMR1i, and pAMR2 conferred comparable increased risk for CV mortality. Significantly increased risk of CV mortality was conferred by biopsies graded as severe AMR (pAMR3)., Conclusions: The new ISHLT pAMR grading schema identifies patients at increased risk of CV mortality, consistent with risks published from several programs before 2011. The current schema is validated by this analysis in a large biopsy database. Because pAMR1h, pAMR1i, and pAMR2 have similar CV risks associated with them, the threshold for a positive diagnosis of pAMR should be re-evaluated in future iterations of the ISHLT schema., (Copyright © 2016 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
11. Gene expression profiling to study racial differences after heart transplantation.
- Author
-
Khush KK, Pham MX, Teuteberg JJ, Kfoury AG, Deng MC, Kao A, Anderson AS, Cotts WG, Ewald GA, Baran DA, Hiller D, Yee J, and Valantine HA
- Subjects
- Adolescent, Adult, Aged, Female, Graft Rejection ethnology, Heart Failure surgery, Humans, Incidence, Male, Middle Aged, Retrospective Studies, Survival Rate trends, United States epidemiology, Young Adult, Gene Expression Profiling methods, Graft Rejection genetics, Heart Transplantation, Racial Groups
- Abstract
Background: The basis for increased mortality after heart transplantation in African Americans and other non-Caucasian racial groups is poorly defined. We hypothesized that increased risk of adverse events is driven by biologic factors. To test this hypothesis in the Invasive Monitoring Attenuation through Gene Expression (IMAGE) study, we determined whether the event rate of the primary outcome of acute rejection, graft dysfunction, death, or retransplantation varied by race as a function of calcineurin inhibitor (CNI) levels and gene expression profile (GEP) scores., Methods: We determined the event rate of the primary outcome, comparing racial groups, stratified by time after transplant. Logistic regression was used to compute the relative risk across racial groups, and linear modeling was used to measure the dependence of CNI levels and GEP score on race., Results: In 580 patients monitored for a median of 19 months, the incidence of the primary end point was 18.3% in African Americans, 22.2% in other non-Caucasians, and 8.5% in Caucasians (p < 0.001). There were small but significant correlations of race and tacrolimus trough levels to the GEP score. Tacrolimus levels were similar among the races. Of patients receiving tacrolimus, other non-Caucasians had higher GEP scores than the other racial groups. African American recipients demonstrated a unique decrease in expression of the FLT3 gene in response to higher tacrolimus levels., Conclusions: African Americans and other non-Caucasian heart transplant recipients were 2.5-times to 3-times more likely than Caucasians to experience outcome events in the Invasive Monitoring Attenuation through Gene Expression study. The increased risk of adverse outcomes may be partly due to the biology of the alloimmune response, which is less effectively inhibited at similar tacrolimus levels in minority racial groups., (Copyright © 2015 International Society for Heart and Lung Transplantation. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
12. Marital status and survival in left ventricular assist device patient populations.
- Author
-
Wright GA, Rauf A, Stoker S, Alharethi R, and Kfoury AG
- Subjects
- Caregivers, Female, Humans, Male, Middle Aged, Retrospective Studies, Survival Rate, Heart Failure mortality, Heart Failure surgery, Heart-Assist Devices, Marital Status
- Published
- 2015
- Full Text
- View/download PDF
13. Prioritizing sensitized heart transplant candidates: a sensitive affair.
- Author
-
Kfoury AG and Kobashigawa JA
- Subjects
- Female, Humans, Male, Heart Transplantation immunology, Immunization statistics & numerical data, Outcome Assessment, Health Care, Tissue and Organ Procurement statistics & numerical data
- Published
- 2012
- Full Text
- View/download PDF
14. Biopsy-diagnosed antibody-mediated rejection based on the proposed International Society for Heart and Lung Transplantation working formulation is associated with adverse cardiovascular outcomes after pediatric heart transplant.
- Author
-
Everitt MD, Hammond ME, Snow GL, Stehlik J, Revelo MP, Miller DV, Kaza AK, Budge D, Alharethi R, Molina KM, and Kfoury AG
- Subjects
- Adolescent, Biopsy, Cardiovascular Diseases epidemiology, Child, Child, Preschool, Female, Follow-Up Studies, Heart Defects, Congenital surgery, Heart Transplantation mortality, Humans, Immunoglobulins metabolism, Infant, International Cooperation, Male, Retrospective Studies, Risk Factors, Societies, Medical, Survival Rate, Antibodies metabolism, Graft Rejection immunology, Graft Rejection pathology, Heart Transplantation immunology, Myocardium immunology, Myocardium pathology, Outcome Assessment, Health Care
- Abstract
Background: There is greater awareness of the pathologic features and clinical implications of antibody-mediated rejection (AMR) after heart transplantation (HT). Yet, compared with adults, the lack of routine surveillance for AMR has limited the growth of evidence in the pediatric population. Herein, we compared outcomes of pediatric HT recipients with and without AMR., Methods: All recipients ≤18 years of age with at least 1 endomyocardial biopsy (EMB) between 1988 and 2009 were included in this study. Assessment for AMR was routine. AMR severity was assigned retrospectively using the proposed 2011 ISHLT grading schema for pathologic AMR (pAMR). Outcome comparisons were made between patients with histologic and immunopathologic evidence for AMR (pAMR 2), those with severe AMR (pAMR 3), and those without evidence of AMR (pAMR 0) or without both histologic and immunopathologic findings (pAMR 1)., Results: Among 1,406 EMBs, pAMR 2 or higher was present in 258 (18%), occurring in 45 of 76 (59%) patients. Of the 17 episodes of pAMR 3 in 9 patients, 6 (35%) were sub-clinical. Mortality was not different between groups. Patients with at least 1 pAMR 3 episode had lower freedom from cardiovascular (CV) mortality or cardiac allograft vasculopathy within 5 years of HT than those without pAMR 3 (45% vs 91%, p < 0.001)., Conclusions: Biopsy findings of AMR (pAMR 2 or higher) are common after pediatric HT. Like cellular rejection, biopsy grading of AMR seems important to delineate those at risk of adverse events. Our results suggest that pAMR 3 is associated with worse CV outcomes. Widespread surveillance for pAMR with a uniform grading system is an important next step to further validate these findings in the pediatric HT population., (Copyright © 2012 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
15. A longitudinal study of the course of asymptomatic antibody-mediated rejection in heart transplantation.
- Author
-
Kfoury AG, Snow GL, Budge D, Alharethi RA, Stehlik J, Everitt MD, Miller DV, Drakos SG, Reid BB, Revelo MP, Gilbert EM, Selzman CH, Bader FM, Connelly JJ, and Hammond ME
- Subjects
- Adolescent, Adult, Aged, Biopsy, Child, Child, Preschool, Female, Follow-Up Studies, Graft Rejection epidemiology, Graft Rejection pathology, Humans, Infant, Infant, Newborn, Male, Middle Aged, Myocardium immunology, Myocardium pathology, Prognosis, Retrospective Studies, Severity of Illness Index, Young Adult, Antibodies immunology, Graft Rejection immunology, Heart Transplantation
- Abstract
Background: Growing evidence suggests worse cardiac allograft vasculopathy and mortality in patients with asymptomatic antibody-mediated rejection (AMR). Debate continues about whether therapeutic intervention is warranted to avoid adverse outcomes. In this study we examine the course of individual episodes of untreated asymptomatic AMR on follow-up endomyocardial biopsy (EMB)., Methods: The U.T.A.H. Cardiac Transplant Program database was queried for transplant recipients between 1985 and 2009 who survived beyond 1 year and had at least 1 episode of lone AMR with a follow-up EMB. All EMBs were screened for AMR by immunofluorescence and graded for severity. Data were analyzed based on time from transplant (early, ≤12 months; late, >12 months)., Results: Nine hundred fifty-eight patients with a total of 15,448 biopsies qualified for the study. Average age at transplant was 46.7 years; 13% of the patients were female. Within the first year post-transplant, asymptomatic AMR was diagnosed in 13.6% of biopsies compared with 5.2% beyond 1 year. AMR resolved in 65% (early) vs 75% (late) on follow-up EMB. More severe AMR was less likely to improve regardless of time from transplant. Furthermore, after an episode of AMR had resolved, the recurrence rate at 3, 6 and 12 months was 44%, 50.1% and 56.2%, respectively., Conclusions: The incidence of AMR is higher in the first year post-transplant and the likelihood of resolution is less on follow-up EMB, especially when more severe. A small but significant number of cases became worse or did not change. These new findings may be helpful in planning future studies that test whether therapeutic interventions on asymptomatic AMR favorably impact outcomes., (Copyright © 2012 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
16. Red cell distribution width, C-reactive protein, the complete blood count, and mortality in patients with coronary disease and a normal comparison population.
- Author
-
Lappé JM, Horne BD, Shah SH, May HT, Muhlestein JB, Lappé DL, Kfoury AG, Carlquist JF, Budge D, Alharethi R, Bair TL, Kraus WE, and Anderson JL
- Subjects
- Aged, Case-Control Studies, Coronary Disease mortality, Female, Humans, Male, Middle Aged, Proportional Hazards Models, Blood Cell Count, C-Reactive Protein metabolism, Coronary Disease blood, Erythrocytes metabolism
- Abstract
Background: Red cell distribution width (RDW) is associated with morbidity and mortality in coronary artery disease (CAD), but the connection of RDW with chronic inflammation is equivocal., Methods: In 1,489 patients with CAD and 8.4-15.2 years of follow-up all-cause mortality and RDW were studied using Cox regression. RDW and its associations with inflammation, liver function, renal function, and body mass were assessed. A population of 449 normal (No-CAD) patients also was evaluated., Results: RDW predicted all-cause mortality in a step-wise manner (HR=1.37 per quintile; 95% CI=1.29, 1.46; p-trend<0.001). A significant but meaningless correlation between RDW and high-sensitivity C-reactive protein (hsCRP) was identified (r=0.181; p<0.001). With full adjustment, RDW remained significant (p-trend<0.001) and the strongest predictor of mortality among all factors included in the model. RDW also strongly predicted all-cause mortality in the normal control population (HR=1.33 per quintile, CI=1.15, 1.55; p-trend<0.001), but hsCRP did not predict mortality among normal controls., Conclusions: RDW was associated with mortality in patients with CAD and may provide clinically useful prognostication. Although RDW was correlated with hsCRP, they were independent predictors of mortality. RDW has been incorporated into risk prediction tool using data from basic chemistries available at: http://intermountainhealthcare.org/IMRS., (Copyright © 2011 Elsevier B.V. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
17. The intermountain risk score predicts incremental age-specific long-term survival and life expectancy.
- Author
-
Horne BD, Muhlestein JB, Lappé DL, Brunisholz KD, May HT, Kfoury AG, Carlquist JF, Alharethi R, Budge D, Whisenant BK, Bunch TJ, Ronnow BS, Rasmusson KD, Bair TL, Jensen KR, and Anderson JL
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Blood Cell Count, Female, Humans, Male, Middle Aged, Predictive Value of Tests, Research Design, Life Expectancy, Mortality, Risk Assessment
- Abstract
The Intermountain Risk Score (IMRS) encapsulates the mortality risk information from all components of the complete blood count (CBC) and basic metabolic profile (BMP), along with age. To individualize the IMRS more clearly, this study evaluated whether IMRS weightings for 1-year mortality predict age-specific survival over more than a decade of follow-up. Sex-specific 1-year IMRS values were calculated for general medical patients with CBC and BMP laboratory tests drawn during 1999-2005. The population was divided randomly 60% (N = 71,921, examination sample) and 40% (N = 47,458, validation sample). Age-specific risk thresholds were established, and both survival and life expectancy were compared across low-, moderate-, and high-risk IMRS categories. During 7.3 ± 1.8 years of follow-up (range, 4.5-11.1 years), the average IMRS of decedents was higher than censored in all age/sex strata (all P < 0.001). For examination and validation samples, every age stratum had incrementally lower survival for higher risk IMRS, with hazard ratios of 2.5-8.5 (P < 0.001). Life expectancies were also significantly shorter for higher risk IMRS (all P < 0.001): For example, among 50-59 year-olds, life expectancy was 7.5, 6.8, and 5.9 years for women with low-, moderate-, and high-risk IMRS (with mortality in 5.7%, 16.3%, and 37.0% of patients, respectively). In Men, life expectancy was 7.3, 6.8, and 5.4 for low-, moderate-, and high-risk IMRS (with patients having 7.3%, 19.5%, and 40.0% mortality), respectively. IMRS significantly stratified survival and life expectancy within age-defined subgroups during more than a decade of follow-up. IMRS may be used to stratify age-specific risk of mortality in research, clinical/preventive, and quality improvement applications. A web calculator is located at http://intermountainhealthcare.org/IMRS., (Copyright © 2011 Mosby, Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
18. Allograft rejection in patients supported with continuous-flow left ventricular assist devices.
- Author
-
Healy AH, Mason NO, Hammond ME, Reid BB, Clayson SE, Drakos SG, Kfoury AG, Patel AN, Bull DA, Budge D, Alharethi RA, Bader FM, Gilbert EM, Stehlik J, and Selzman CH
- Subjects
- Female, Humans, Male, Middle Aged, Prosthesis Design, Retrospective Studies, Graft Rejection epidemiology, Heart Transplantation, Heart-Assist Devices
- Abstract
Background: Both pulsatile-flow and continuous-flow left ventricular assist devices (LVADs) successfully provide patients a bridge to transplantation. Some data suggest that continuous-flow pumps increase the risk of allograft rejection, contributing to posttransplantation morbidity and mortality. We sought to analyze the relationship between LVAD flow characteristics and subsequent allograft rejection in bridge to transplant (BTT) patients., Methods: Patients with LVADs from the UTAH Transplant Affiliated Hospitals were retrospectively analyzed. Rejection was determined pathologically according to the International Society for Heart and Lung Transplantation revised cardiac allograft rejection scale. Multimodal statistical analyses were applied., Results: Of 1,076 patients who underwent transplantation over a 26-year period, 151 had LVADs. Of these, 111 (77 pulsatile flow, 34 continuous flow) patients had pathologic data available. There was no difference in overall rejection (grades 1R to 3R) between the pulsatile-flow LVAD and continuous-flow LVAD groups (2.00 ± 1.43 versus 1.50 ± 1.16 episodes/year; p = 0.076.) Patients with pulsatile-flow LVADs had more clinically relevant (grades 2R to 3R) rejection than did patients with continuous-flow LVADs (0.49 ± 0.72 versus 0.12 ± 0.33 episodes/year; p < 0.001). There was no survival difference at 1 year (p = 0.920) or 4 years (p = 0.721) after transplantation., Conclusions: Patients with continuous-flow LVADs have similar overall rejection rates and a reduced rate of clinically relevant rejection compared with patients with pulsatile-flow LVADs during the first year after transplantation. Although there is theoretical concern that nonphysiologic, nonpulsatile flow could alter the neurohormonal profile of patients in heart failure, we are encouraged that the type of LVAD circulation does not influence posttransplantation allograft survival., (Copyright © 2011 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
19. Changing outcomes in patients bridged to heart transplantation with continuous- versus pulsatile-flow ventricular assist devices: an analysis of the registry of the International Society for Heart and Lung Transplantation.
- Author
-
Nativi JN, Drakos SG, Kucheryavaya AY, Edwards LB, Selzman CH, Taylor DO, Hertz MI, Kfoury AG, and Stehlik J
- Subjects
- Adult, Female, Graft Rejection epidemiology, Heart-Assist Devices trends, Humans, International Cooperation, Male, Middle Aged, Prevalence, Pulsatile Flow, Retrospective Studies, Survival Rate, Treatment Outcome, Heart Failure mortality, Heart Failure therapy, Heart Transplantation, Heart-Assist Devices classification, Registries
- Abstract
Background: Patients bridged to heart transplantation with left ventricular assist devices (LVADs) have been reported to have higher post-transplant mortality compared with those without LVADs. Our aim was to determine the impact of the type of LVAD and implant era on post-transplant survival., Methods: In this study we included 8,557 patients from the registry of the International Society for Heart and Lung Transplantation. We examined post-transplant outcomes in 1,100 patients bridged to transplant with pulsatile-flow LVADs between January 2000 and June 2004 (first era), 880 patients bridged with pulsatile-flow LVADs between July 2004 and May 2008 (second era), and 417 patients bridged with continuous-flow LVADs in the second era. Patients who required intravenous inotropes but not LVAD support (n = 2,728) and patients who did not require either LVAD or inotropes (n = 3,432) served as controls., Results: Post-transplant survival of patients bridged with pulsatile LVADs improved significantly between the first and the second era (p = 0.03). In the second era, there was no significant difference in post-transplant survival of patients bridged with pulsatile- vs continuous-flow LVADs (p = 0.26), and survival rates in the 2 groups were not statistically different from that of the non-LVAD group. Graft rejection was similar in patients bridged with LVADs compared to those without LVADs., Conclusions: In the most recent era, the use of either pulsatile- or continuous-flow LVADs did not result in increased post-transplant mortality. This finding is important as the proportion of patients with LVADs at the time of transplant has been rising., (Published by Elsevier Inc.)
- Published
- 2011
- Full Text
- View/download PDF
20. Would access to device therapies improve transplant outcomes for adults with congenital heart disease? Analysis of the United Network for Organ Sharing (UNOS).
- Author
-
Everitt MD, Donaldson AE, Stehlik J, Kaza AK, Budge D, Alharethi R, Bullock EA, Kfoury AG, and Yetman AT
- Subjects
- Adult, Defibrillators, Implantable, Female, Heart Failure etiology, Heart-Assist Devices, Humans, Male, Middle Aged, Treatment Outcome, Waiting Lists, Heart Defects, Congenital mortality, Heart Defects, Congenital therapy, Heart Failure mortality, Heart Transplantation mortality
- Abstract
Background: Patients with congenital heart disease (CHD) now survive into adulthood and often present with end-stage heart failure (HF). HF management and approach to orthotopic heart transplant (OHT) may differ from adults without CHD. We sought to compare OHT waitlist characteristics and outcomes for these 2 groups., Methods: The Organ Procurement and Transplantation Network (OPTN)/United Network for Organ Sharing (UNOS) database was used to identify adults (≥18 years) listed for OHT from 2005 to 2009. The cohort was divided into those with or without CHD., Results: Of 9,722 adults included, 314 (3%) had CHD. Adults with CHD were younger (35 ± 13 vs 52 ± 12 years, p < 0.01) and more often had undergone prior cardiac surgery (85% vs. 34%, p < 0.01). Patients with CHD were less likely to have a defibrillator (44% vs 75%, p < 0.01) or ventricular assist device (5% vs 14%, p < 0.01) and were more likely to be listed at the lowest urgency status than patients without CHD (64% vs 44%, p < 0.01). Fewer CHD patients achieved OHT (53% vs 65%, p < 0.001). Although overall waitlist mortality did not differ between groups (10% vs 8%, p = 0.15), patients with CHD were more likely to experience cardiovascular death (60% vs 40%, p = 0.03), including sudden in 44% and due to HF in 16%., Conclusions: Despite lower urgency status, patients with CHD have greater cardiovascular mortality awaiting OHT than those without. Increased defibrillator use could improve survival to OHT, because sudden death is common. VAD support may benefit select patients, but experience in CHD is limited. Referral to specialized adult congenital heart centers can enhance utilization of device therapies and potentially improve waitlist outcomes., (Copyright © 2011 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
21. Report from a consensus conference on antibody-mediated rejection in heart transplantation.
- Author
-
Kobashigawa J, Crespo-Leiro MG, Ensminger SM, Reichenspurner H, Angelini A, Berry G, Burke M, Czer L, Hiemann N, Kfoury AG, Mancini D, Mohacsi P, Patel J, Pereira N, Platt JL, Reed EF, Reinsmoen N, Rodriguez ER, Rose ML, Russell SD, Starling R, Suciu-Foca N, Tallaj J, Taylor DO, Van Bakel A, West L, Zeevi A, and Zuckermann A
- Subjects
- Antibodies blood, Graft Rejection pathology, Heart Transplantation pathology, Humans, Treatment Outcome, Graft Rejection immunology, Heart Transplantation immunology
- Abstract
Background: The problem of AMR remains unsolved because standardized schemes for diagnosis and treatment remains contentious. Therefore, a consensus conference was organized to discuss the current status of antibody-mediated rejection (AMR) in heart transplantation., Methods: The conference included 83 participants (transplant cardiologists, surgeons, immunologists and pathologists) representing 67 heart transplant centers from North America, Europe, and Asia who all participated in smaller break-out sessions to discuss the various topics of AMR and attempt to achieve consensus., Results: A tentative pathology diagnosis of AMR was established, however, the pathologist felt that further discussion was needed prior to a formal recommendation for AMR diagnosis. One of the most important outcomes of this conference was that a clinical definition for AMR (cardiac dysfunction and/or circulating donor-specific antibody) was no longer believed to be required due to recent publications demonstrating that asymptomatic (no cardiac dysfunction) biopsy-proven AMR is associated with subsequent greater mortality and greater development of cardiac allograft vasculopathy. It was also noted that donor-specific antibody is not always detected during AMR episodes as the antibody may be adhered to the donor heart. Finally, recommendations were made for the timing for specific staining of endomyocardial biopsy specimens and the frequency by which circulating antibodies should be assessed. Recommendations for management and future clinical trials were also provided., Conclusions: The AMR Consensus Conference brought together clinicians, pathologists and immunologists to further the understanding of AMR. Progress was made toward a pathology AMR grading scale and consensus was accomplished regarding several clinical issues., (Copyright © 2011 International Society for Heart and Lung Transplantation. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
22. Antibody testing for cardiac antibody-mediated rejection: which panel correlates best with cardiovascular death?
- Author
-
Revelo MP, Stehlik J, Miller D, Snow GL, Everitt MD, Budge D, Bader FM, Alharethi RA, Gilbert EM, Reid BB, Selzman CH, Hammond ME, and Kfoury AG
- Subjects
- Adolescent, Adult, Aged, Antibodies immunology, Biomarkers blood, Biopsy, Complement C3d metabolism, Complement C4b, Female, Fibrin metabolism, Graft Rejection epidemiology, HLA-DR Antigens blood, Heart Transplantation pathology, Humans, Infant, Infant, Newborn, Male, Middle Aged, Myocardium pathology, Peptide Fragments blood, Prognosis, Proportional Hazards Models, Retrospective Studies, Risk Factors, Survival Rate, Young Adult, Antibodies blood, Graft Rejection diagnosis, Graft Rejection immunology, Heart Transplantation immunology, Heart Transplantation mortality
- Abstract
Background: Recent efforts are being undertaken to update and refine current diagnostic criteria for antibody-mediated rejection (AMR) in heart transplantation. We believe that the appropriate reactants are those that best predict the adverse consequences of AMR and therefore tested various models using different reactants to find the best predictors of cardiovascular mortality in pathologically defined AMR., Methods: The study group included only patients in whom all immunofluorescence antibodies of interest had been tested on biopsy specimens obtained after 2002 when C4d was routinely added. We analyzed our data using 3 Cox proportional hazard models with time-varying covariates using an end point of cardiovascular mortality, as previously defined., Results: In 3,712 biopsy specimens from 422 patients, the 2-antibody model achieved a value of R(2) = 0.930 using C3d and C4d antibodies alone. A model that used 4 antibodies--C3d, C4d, human leukocyte antigen-D related (HLA-DR) and fibrin--was superior (R(2) = 0.988). The model that best predicted cardiovascular mortality included all 6 antibodies: HLA-DR, immunoglobulin (Ig) G, IgM, C3d, C4d, and fibrin (R(2) = 0.989). The models using 4 or 6 antibodies were significantly superior to the model using only C3d and C4d (for each interaction, p < 0.0001)., Conclusions: The combination of complement components, HLA-DR and fibrin, is valuable in defining AMR in patients at risk for allograft loss from cardiovascular causes. Fibrin is particularly important for detecting the presence of severe AMR, with a high likelihood of poor long-term patient outcome., (Copyright © 2011 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
23. End-of-life decision making and implementation in recipients of a destination left ventricular assist device.
- Author
-
Brush S, Budge D, Alharethi R, McCormick AJ, MacPherson JE, Reid BB, Ledford ID, Smith HK, Stoker S, Clayson SE, Doty JR, Caine WT, Drakos S, and Kfoury AG
- Subjects
- Adult, Aged, Aged, 80 and over, Comorbidity, Female, Heart Transplantation, Humans, Male, Middle Aged, Professional-Family Relations, Qualitative Research, Quality of Life, Time Factors, Young Adult, Caregivers psychology, Decision Making, Heart Failure mortality, Heart Failure surgery, Heart-Assist Devices, Terminal Care
- Abstract
Background: The use of left ventricular assist devices (LVADs) as destination therapy (DT) is increasing and has proven beneficial in prolonging survival and improving quality of life in select patients with end-stage heart failure. Nonetheless, end-of-life (EOL) issues are inevitable and how to approach them underreported., Methods: Our DT data registry was queried for eligible patients, defined as those individuals who actively participated in EOL decision making. The process from early EOL discussion to palliation and death was reviewed. We recorded the causes leading to EOL discussion, time from EOL decision to withdrawal and from withdrawal to death, and location. Primary caregivers were surveyed to qualify their experience and identify themes relevant to this process., Results: Between 1999 and 2009, 92 DT LVADs were implanted in 69 patients. Twenty patients qualified for inclusion (mean length of support: 833 days). A decrease in quality of life from new/worsening comorbidities usually prompted EOL discussion. Eleven patients died at home, 8 in the hospital and 1 in a nursing home. Time from EOL decision to LVAD withdrawal ranged from <1 day to 2 weeks and from withdrawal until death was <20 minutes in all cases. Palliative care was provided to all patients. Ongoing assistance from the healthcare team facilitated closure and ensured comfort at EOL., Conclusions: With expanding indications and improved technology, more DT LVADs will be implanted and for longer durations, and more patients will face EOL issues. A multidisciplinary team approach with protocols involving DT patients and their families in EOL decision making allows for continuity of care and ensures dignity and comfort at EOL., (Copyright © 2010 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
24. Effect of preservation solution choice on antibody-mediated rejection after heart transplantation.
- Author
-
Verma DR, Drakos SG, Stehlik J, Horne BD, and Kfoury AG
- Subjects
- Adult, Disaccharides therapeutic use, Electrolytes therapeutic use, Female, Glutamates therapeutic use, Glutathione therapeutic use, Histidine therapeutic use, Humans, Male, Mannitol therapeutic use, Middle Aged, Myocardial Reperfusion Injury prevention & control, Treatment Outcome, Graft Rejection immunology, Graft Rejection prevention & control, Heart Failure surgery, Heart Transplantation immunology, Organ Preservation Solutions therapeutic use
- Published
- 2010
- Full Text
- View/download PDF
25. Prolonged allograft ischemic time is not associated with higher incidence of antibody-mediated rejection.
- Author
-
Singhal AK, Drakos SG, Kfoury AG, Horne BD, Verma DR, and Stehlik J
- Subjects
- Adult, Antibodies blood, Graft Rejection epidemiology, Humans, Incidence, Myocardial Reperfusion Injury, Retrospective Studies, Time Factors, Transplantation, Homologous, Treatment Outcome, Graft Rejection immunology, Graft Survival immunology, Heart Transplantation methods
- Published
- 2010
- Full Text
- View/download PDF
26. Temporal trends in heart transplantation from high-risk donors: are there lessons to be learned? A multi-institutional analysis.
- Author
-
Nativi JN, Brown RN, Taylor DO, Kfoury AG, Kirklin JK, and Stehlik J
- Subjects
- Age Factors, Diabetes Complications complications, Echocardiography, Humans, Hypertension complications, Risk Factors, Sex Factors, United States, Graft Rejection epidemiology, Heart Transplantation trends, Tissue Donors
- Abstract
Background: In 2003 the Department of Health and Human Services sponsored the Organ Donation Breakthrough Collaborative (ODBC) with the aim to increase organ donation. After the ODBC, increases in the number of all solid organs transplanted, except for heart, were seen. The aim of this study was to determine if ODBC resulted in temporal changes in the use of hearts from high-risk donors., Methods: We analyzed data from the Cardiac Transplant Research Database in three eras: 1990-1995, 1996-2002, and 2003-2007. We explored temporal changes in high-risk donor characteristics: age, gender, hypertension, diabetes mellitus, abnormal echocardiogram, and ischemic time., Results: Between 1990 and 2007, 7,220 patients underwent transplantation in 26 centers. Donors in the first era were least likely to have high-risk characteristics of higher age (mean, 30 years), female gender (30%), hypertension (8%), diabetes mellitus (1%), structural abnormalities on echocardiogram (7%), and prolonged graft ischemic time (mean, 163 minutes). In the second era, there was a significant increase in the use of donors with the above mentioned high-risk characteristics-32 years, 33%, 10%, 3%, 8% and 181 minutes, respectively. In the third post-ODBC era, no further increase was seen in high-risk donors, but rather a trend for avoidance of risk-32 years, 28%, 10%, 2%, 5% and 186 minutes, respectively., Conclusion: Significant temporal changes in the characteristics of heart donors have occurred in the past 17 years. Recent temporal changes, however, cannot be directly attributed to the ODBC efforts., (Published by Elsevier Inc.)
- Published
- 2010
- Full Text
- View/download PDF
27. Controversies in defining cardiac antibody-mediated rejection: need for updated criteria.
- Author
-
Kfoury AG and Hammond ME
- Subjects
- Graft Rejection physiopathology, Heart Transplantation physiology, Humans, Immunity, Humoral physiology, Tissue Donors, Transplantation, Homologous, Antibodies physiology, Graft Rejection immunology, Heart Transplantation immunology
- Abstract
Recent years have seen a rising awareness of the significance of cardiac antibody-mediated rejection (AMR) as a result of its formal recognition by the International Society for Heart and Lung Transplantation. New insights on the pathology and clinical behavior of cardiac AMR are at odds with current diagnostic guidelines. This perspective examines some of the contentious and unresolved issues in cardiac AMR as the transplant community makes concrete steps towards updating its defining criteria.
- Published
- 2010
- Full Text
- View/download PDF
28. Effects of the 2006 U.S. thoracic organ allocation change: analysis of local impact on organ procurement and heart transplantation.
- Author
-
Nativi JN, Kfoury AG, Myrick C, Peters M, Renlund D, Gilbert EM, Bader F, Singhal AK, Everitt M, Fisher P, Bull DA, Selzman C, and Stehlik J
- Subjects
- Adult, Female, Heart Diseases mortality, Heart Diseases therapy, Heart Transplantation economics, Heart Transplantation statistics & numerical data, Heart-Assist Devices, Humans, Male, Middle Aged, Resource Allocation economics, Resource Allocation statistics & numerical data, Survival Rate, Tissue and Organ Procurement economics, Tissue and Organ Procurement statistics & numerical data, United States, Waiting Lists, Health Policy trends, Heart Transplantation trends, Resource Allocation trends, Tissue and Organ Procurement trends
- Abstract
Background: The United Network for Organ Sharing (UNOS) implemented a thoracic organ allocation policy change (APC) in July 2006 that aimed to reduce death on the waiting list by expanding regional organ sharing. As such, organs would be allocated to the sickest recipients with highest listing status across the region. Our aim was to determine the impact of the new policy on the procurement and transplant process within our program., Methods: We analyzed data supplied by UNOS as the contractor for the Organ Procurement and Transplantation Network and from the local organ procurement organization for 2 years before and 2 years after implementation of the APC., Results: The APC resulted in an increase in the proportion of Status 1A patients transplanted (24% to 43%, p = 0.015) and a decrease in the proportion of Status 2 patients transplanted (56% to 24%, p = 0.001). Significant increases were observed in mean graft ischemic time (196 minutes to 223 minutes, p = 0.022), number of patients transplanted with ventricular assist devices (17% to 31%, p = 0.036), and procurement costs. There was no significant difference in waiting-list mortality (6% to 5%, p = 0.75) and short-term post-transplant survival., Conclusions: The 2006 change in UNOS organ allocation policy resulted in an increase in Status 1A transplants, graft ischemic time and procurement costs, and a decrease in Status 2 transplants, but no effect on mortality on the waiting list within our center. To assess the full effect of the APC on outcomes, the long-term impact of the increased graft ischemic time on survival should be quantified.
- Published
- 2010
- Full Text
- View/download PDF
29. A novel non-invasive method to assess aortic valve opening in HeartMate II left ventricular assist device patients using a modified Karhunen-Loève transformation.
- Author
-
Bishop CJ, Mason NO, Kfoury AG, Lux R, Stoker S, Horton K, Clayson SE, Rasmusson B, and Reid BB
- Subjects
- Algorithms, Aortic Valve diagnostic imaging, Aortic Valve Stenosis epidemiology, Aortic Valve Stenosis physiopathology, Echocardiography, Feedback, Physiological physiology, Fourier Analysis, Humans, Retrospective Studies, Risk Factors, Ventricular Function, Left physiology, Aortic Valve physiopathology, Electrophysiologic Techniques, Cardiac methods, Heart-Assist Devices classification
- Abstract
Background: Thrombus formation on or near the aortic valve has been reported in HeartMate II (Thoratec, Pleasanton, CA) left ventricular assist device (LVAD) patients whose aortic valves do not open. With an akinetic valve, thrombogenesis is more likely. Thrombus formation may lead to neurologic events, placing the patient at greater risk. Aortic valve stenosis and/or regurgitation have also been observed with akinetic aortic valves. Assessing aortic valve opening is crucial when optimizing rotations per minute (rpm) to minimize embolic risk and aortic valve stenosis but presently relies solely on echocardiography, intermittent decreases in rpms to force aortic valve opening, and monitoring of pulse pressure. We hypothesized the electrical current waveforms of the HeartMate II would reveal whether the aortic valve was opening due to pressure changes in the left ventricle to allow for continuous monitoring and control of aortic valve opening ratios., Methods: Electrical HeartMate II current waveforms of patients from 2008 to 2009 that were recorded at the time of echocardiograph procedures were analyzed using a modified Karhunen-Loève transformation with a training set of electrical waveforms from 8,860 HeartMate II electrical current recordings from 2001 to 2009., Results: The study included 6 patients. The electrical current magnitude of the projection of the electrical current waveforms onto the training set's eigenvectors was statistically significantly greater in 4 of the 6 patients when the aortic valve was closed, confirmed by echocardiography. The 2 patients who did not have a large increase in the magnitude had mild aortic valve regurgitation., Conclusion: Electrical current analysis for rotary non-pulsatile pumps is a means to develop a physiologic feedback algorithm for an auto-mode, which currently does not exist. Constant regulation and optimization of rotary non-pulsatile LVADs would minimize patients' risk for neurologic events and aortic valve stenosis., (Copyright (c) 2010 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
30. Effect of ABO-incompatible listing on infant heart transplant waitlist outcomes: analysis of the United Network for Organ Sharing (UNOS) database.
- Author
-
Everitt MD, Donaldson AE, Casper TC, Stehlik J, Hawkins JA, Tani LY, Renlund DG, Kouretas PC, Kaza AK, Bullock EA, Cardon M, and Kfoury AG
- Subjects
- Heart Diseases mortality, Humans, Infant, Infant, Newborn, Retrospective Studies, Survival Rate trends, Time Factors, Tissue Donors statistics & numerical data, United States epidemiology, ABO Blood-Group System, Blood Group Incompatibility epidemiology, Databases, Factual, Heart Diseases surgery, Heart Transplantation statistics & numerical data, Waiting Lists
- Abstract
Background: Midterm heart transplant outcomes of ABO-incompatible (ABO-I) organ use in infants are favorable. ABO-I transplantation has resulted in reduced waitlist mortality in some countries. This study assessed the effect of an ABO-I listing strategy on pre-transplant outcomes in the United States., Methods: The Organ Procurement and Transplantation Network (OPTN)/United Network of Organ Sharing (UNOS) database was used to identify infants aged younger than 1 year listed as status 1 for heart transplantation between January 1, 2001, and May 20, 2008. The cohort was divided into 2 groups: eligible for ABO-compatible (ABO-C) transplant and eligible for ABO-I transplant. Baseline characteristics, waitlist times, and outcomes were compared in univariate analysis. Competing risks analysis evaluated differences in time to transplant in the presence of other outcomes., Results: Of 1,029 infants listed for transplant, 277 (27%) were listed for an ABO-I transplant. Overall, 92% of transplant recipients received an ABO-C organ regardless of listing type. Among recipients eligible for ABO-I, only 27% received an ABO-I organ. The percentage that underwent transplant in each group did not differ. Although infants listed for an ABO-I organ had a shorter wait time for transplant, waitlist mortality was similar., Conclusions: Despite the intended merits of ABO-I heart transplantation, ABO-I listing and organ acceptance have not yielded lower waitlist mortality in the United States under the current UNOS allocation algorithm. Consideration should be given to altering the allocation system to one that gives less preference toward blood group compatibility in hopes of improving organ use and reducing waitlist mortality.
- Published
- 2009
- Full Text
- View/download PDF
31. Utility of virtual crossmatch in sensitized patients awaiting heart transplantation.
- Author
-
Stehlik J, Islam N, Hurst D, Kfoury AG, Movsesian MA, Fuller A, Delgado JC, Hammond ME, Gilbert EM, Renlund DG, Bader F, Fisher PW, Bull DA, Singhal AK, and Eckels DD
- Subjects
- Biomarkers blood, Endomyocardial Fibrosis epidemiology, Endomyocardial Fibrosis mortality, Follow-Up Studies, Histocompatibility Testing methods, Humans, Hypoxia-Inducible Factor 1, alpha Subunit blood, Postoperative Complications epidemiology, Postoperative Complications immunology, Postoperative Complications mortality, Postoperative Complications prevention & control, Procollagen-Proline Dioxygenase blood, Time Factors, User-Computer Interface, Vascular Endothelial Growth Factor A blood, Heart Transplantation immunology
- Abstract
Background: Organ transplant candidates with serum antibodies directed against human leukocyte antigens (HLA) face longer waiting times and higher mortality while awaiting transplantation. This study examined the accuracy of virtual crossmatch, in which recipient HLA-specific antibodies, identified by solid-phase assays, are compared to the prospective donor HLA-type in heart transplantation., Methods: We examined the accuracy of virtual crossmatch in predicting immune compatibility of donors and recipients in heart transplantation and clinical outcomes in immunologically sensitized heart transplant recipients in whom virtual crossmatch was used in allograft allocation., Results: Based on analysis of 257 T-cell antihuman immunoglobulin complement-dependent cytotoxic (AHG-CDC) crossmatch tests, the positive predictive value of virtual crossmatch (the likelihood of an incompatible virtual crossmatch resulting in an incompatible T-cell CDC-AHG crossmatch) was 79%, and the negative predictive value of virtual crossmatch (the likelihood of a compatible virtual crossmatch resulting in a compatible T-cell CDC-AHG crossmatch) was 92%. When used in a cohort of 28 sensitized patients awaiting heart transplantation, 14 received allografts based on a compatible virtual crossmatch alone from donors in geographically distant locations. Compared with the other 14 sensitized patients who underwent transplant after a compatible prospective serologic crossmatch, the rejection rates and survival were similar., Conclusion: Our findings are evidence of the accuracy of virtual crossmatch and its utility in augmenting the opportunities for transplantation of sensitized patients.
- Published
- 2009
- Full Text
- View/download PDF
32. Prior human leukocyte antigen-allosensitization and left ventricular assist device type affect degree of post-implantation human leukocyte antigen-allosensitization.
- Author
-
Drakos SG, Kfoury AG, Kotter JR, Reid BB, Clayson SE, Selzman CH, Stehlik J, Fisher PW, Merida M 3rd, Eckels DD, Brunisholz K, Horne BD, Stoker S, Li DY, and Renlund DG
- Subjects
- Adult, Antibodies immunology, Antibody Formation, Female, Heart Failure therapy, Humans, Male, Middle Aged, Retrospective Studies, HLA Antigens immunology, Heart Failure immunology, Heart Transplantation, Heart-Assist Devices
- Abstract
Left ventricular assist device (LVAD) implantation before heart transplantation has been associated with formation of antibodies directed against human leukocyte antigens (HLA), often referred to as sensitization. This study investigated whether prior sensitization or LVAD type affected the degree of post-implantation sensitization. The records of consecutive HeartMate (HM) I and HM II LVAD patients were reviewed. Panel reactive antibody (PRA) was assessed before LVAD implantation and biweekly thereafter. Sensitization was defined as PRA > 10%, and high-degree sensitization was defined as PRA > 90%. An HM LVAD was implanted in 64 patients, and 11 received a HM II LVAD as a bridge to transplant. Ten HM I patients (16%) were sensitized before LVAD implantation (HM I-S), and 54 (84%) were not (HM I-Non-S). Nine HM I-S patients (90%) became highly sensitized (PRA > 90%) compared with 9 HM I-Non-S patients (16.7%; p < 0.001). The PRA remained elevated (> 90%) in 8 of the 9 (88.9%) highly sensitized HM I-S patients vs 5 of the 9 (55.6%) HM I-Non-S highly sensitized patients. The PRA levels in the rest of the HM I-S highly sensitized patients declined from 93% +/- 4% to 55% +/- 15% (p = 0.01). Among the 11 HM II patients, 1 (9%) was sensitized before LVAD implantation (PRA, 40%) and the PRA moderately increased to 80%. No other HM II patient became sensitized after implantation. Thus, 1 of 11 (9%) HM II patients became sensitized compared with 29 of 64 (45%) HM I patients (p = 0.04). Pre-sensitized patients are at higher risk for becoming and remaining highly HLA-allosensitized after LVAD implantation. The HeartMate II LVAD appears to cause less sensitization than HeartMate I.
- Published
- 2009
- Full Text
- View/download PDF
33. Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection.
- Author
-
Kfoury AG, Hammond ME, Snow GL, Drakos SG, Stehlik J, Fisher PW, Reid BB, Everitt MD, Bader FM, and Renlund DG
- Subjects
- Adult, Antibodies immunology, Cardiovascular Diseases immunology, Female, Graft Rejection pathology, Humans, Immunity, Cellular immunology, Male, Middle Aged, Survival Analysis, Cardiovascular Diseases mortality, Graft Rejection immunology, Heart Transplantation immunology, Heart Transplantation mortality
- Abstract
Background: Little has been reported on the clinical significance of asymptomatic antibody-mediated rejection (AMR) alone or mixed rejection (MR), defined as concurrent cellular rejection (CR) and AMR in heart transplantation. In this study, we examined whether a differential impact on cardiovascular mortality (CVM) existed when comparing asymptomatic AMR, to stable MR or CR., Methods: The Utah Transplantation Affiliated Hospitals (UTAH) Cardiac Transplant Program pathology database of all heart transplant recipients between 1985 and 2004 was queried. Patients were classified as cellular, antibody-mediated, or mixed rejectors based on their predominant pattern of rejection type in the first three months post-transplant. Kaplan-Meier survival curves were fit to each of the three groups and analyses were adjusted for age at the time of transplant, gender, and underlying primary cardiac disease., Results: Eight hundred and sixty nine heart transplant recipients qualified for analysis. Over the study period, patients with asymptomatic AMR or stable MR patterns had significantly worse CVM when compared to patients with stable CR pattern (AMR, 21.2%; MR, 18.0%; CR, 12.6%; AMR vs. CR, p = 0.009; MR vs. CR, p = 0.001). In contrast, CVM was comparable in patients with asymptomatic AMR or stable MR patterns (p = 0.9)., Conclusions: Asymptomatic or subclinical AMR and MR are clinically relevant, should be recognized, and deserve consideration for therapeutic intervention in hopes of avoiding adverse outcomes.
- Published
- 2009
- Full Text
- View/download PDF
34. Tuberculosis in a solid-organ transplant recipient: modern-day implications.
- Author
-
Jazrawi A, Jones M, Kfoury AG, Fisher PW, Gilbert EM, Bader F, Pombo D, Hanson KE, and Stehlik J
- Subjects
- Anti-Bacterial Agents therapeutic use, Cardiomyopathies surgery, Drug Therapy, Combination, Humans, Male, Postoperative Complications diagnostic imaging, Tomography, X-Ray Computed, Treatment Outcome, Tuberculosis diagnostic imaging, Tuberculosis drug therapy, Young Adult, Antitubercular Agents therapeutic use, Heart Transplantation adverse effects, Postoperative Complications microbiology, Tuberculosis diagnosis
- Abstract
The clinical presentation and disease course of tuberculosis (TB) in a solid-organ transplant (SOT) recipient may be atypical and the risk of mortality is high. Herein we examine the role of the different tests used in diagnosis of TB and review the specifics of anti-mycobacterial therapy and the public health implications of TB in a SOT recipient.
- Published
- 2009
- Full Text
- View/download PDF
35. A clinical correlation study of severity of antibody-mediated rejection and cardiovascular mortality in heart transplantation.
- Author
-
Kfoury AG, Renlund DG, Snow GL, Stehlik J, Folsom JW, Fisher PW, Reid BB, Clayson SE, Gilbert EM, Everitt MD, Bader FM, Singhal AK, and Hammond ME
- Subjects
- Adult, Biopsy, Cardiovascular Diseases physiopathology, Female, Graft Rejection mortality, Heart Transplantation pathology, Humans, Isoantibodies blood, Male, Middle Aged, Proportional Hazards Models, Regression Analysis, Retrospective Studies, Severity of Illness Index, Survival Rate, Utah epidemiology, Cardiovascular Diseases mortality, Graft Rejection physiopathology, Heart Transplantation immunology, Heart Transplantation mortality
- Abstract
Background: The current International Society for Heart and Lung Transplantation (ISHLT) diagnostic criteria for antibody-mediated rejection (AMR) designate AMR as either absent (AMR 0) or present (AMR 1), without grading its severity. Yet, the extent of histologic and immunofluorescence (IF) findings of AMR varies across endomyocardial biopsies (EMBs). In this study, we hypothesized that the severity of AMR, as assessed on EMBs, correlates with cardiovascular mortality in heart transplant recipients., Methods: All EMBs from 1985 to 2005 were evaluated. Biopsy specimens were uniformly studied by light microscopy and IF early post-transplant. A comprehensive vascular score (V1: no AMR, to V5: severe AMR) was prospectively assigned to each EMB, based on severity of both histologic and IF findings. Univariate Cox proportional hazards regressions were performed using indicators of vascular scores alone, combined, and cumulatively., Results: Nine hundred six patients were transplanted and included in the study. Mean age was 46.6 +/- 15.5 years and 82% were male. A total of 26,236 EMBs comprised the study data. As expected, histologic and immunopathologic findings of AMR varied in severity. An incremental risk of cardiovascular mortality was found with more severe AMR whether vascular scores were analyzed individually (p = 0.001), in combination (p = 0.01) or cumulatively (p = 0.006)., Conclusions: The severity of AMR on EMBs correlates with an incremental cardiovascular mortality risk after heart transplantation, suggesting that AMR should be viewed as a spectrum rather than just as present or absent. Supplementing the ISHLT AMR diagnostic guidelines with a consensus severity scale is warranted.
- Published
- 2009
- Full Text
- View/download PDF
36. Early screening for antibody-mediated rejection in heart transplant recipients.
- Author
-
Kfoury AG, Hammond ME, Snow GL, Stehlik J, Reid BB, Long JW, Gilbert EM, Bader FM, Bull DA, and Renlund DG
- Subjects
- Adult, Algorithms, Biopsy, Complement System Proteins immunology, Female, Heart Transplantation adverse effects, Humans, Immunoglobulins immunology, Immunosuppression Therapy methods, Immunosuppressive Agents therapeutic use, Male, Middle Aged, Muromonab-CD3 therapeutic use, Myocardium immunology, Myocardium pathology, Retrospective Studies, Antibodies immunology, Graft Rejection diagnosis, Graft Rejection immunology, Heart Transplantation immunology, Mass Screening methods
- Abstract
Background: The International Society for Heart and Lung Transplantation (ISHLT) recently established a diagnostic scheme for antibody-mediated rejection (AMR). Currently, however, confirmatory immunohistochemistry studies are recommended only if AMR is clinically or histologically suspected. In this study, we examine whether a pattern of repetitive AMR occurred early enough after transplantation to warrant prospective immunohistochemistry screening in all recently transplanted recipients., Methods: We queried our pathology database of adult and pediatric endomyocardial biopsies (EMBs) from 1985 to 2005. All EMB specimens were prospectively studied by immunofluorescence in the early post-operative period. AMR was defined as the presence of complement and immunoglobulin deposits on frozen section. Only patients classified as antibody-mediated rejectors (>or=3 episodes of AMR) were included. Cumulative incidence and time from transplant to first and third AMR episodes were obtained., Results: Three hundred seventy-five of 870 heart transplant recipients had >or=3 episodes of AMR. Mean age of recipients was 45.6 years and 78% were male. A total of 19,569 EMBs comprised the study data. By 100 days post-transplant, 85% of patients had their first and 54% their third AMR. In addition, patients showed a clear trend of early clustering of AMR-positive biopsies. Results were similar regardless of whether or not muromonab-CD3 (Orthoclone OKT3) induction was used., Conclusions: We advocate early immunohistochemical surveillance testing for AMR to supplement the diagnostic algorithm established by the ISHLT, because a pattern of AMR becomes manifest soon after transplantation. This change will allow earlier detection of asymptomatic AMR and may prompt changes in immunosuppression strategies to avoid adverse outcomes.
- Published
- 2007
- Full Text
- View/download PDF
37. Molecular testing for long-term rejection surveillance in heart transplant recipients: design of the Invasive Monitoring Attenuation Through Gene Expression (IMAGE) trial.
- Author
-
Pham MX, Deng MC, Kfoury AG, Teuteberg JJ, Starling RC, and Valantine H
- Subjects
- Cause of Death, Diagnosis, Differential, Echocardiography, Follow-Up Studies, Humans, Incidence, Prospective Studies, Reproducibility of Results, Severity of Illness Index, Survival Rate, Time Factors, Transplantation, Homologous, Gene Expression, Gene Expression Profiling, Graft Rejection diagnosis, Graft Rejection epidemiology, Graft Rejection genetics, Heart Transplantation, Molecular Diagnostic Techniques methods, Monitoring, Physiologic methods, Myocardium pathology
- Abstract
Background: Acute rejection continues to occur beyond the first year after cardiac transplantation, but the optimal strategy for detecting rejection during this late period is still controversial. Gene expression profiling (GEP), with its high negative predictive value for acute cellular rejection (ACR), appears to be well suited to identify low-risk patients who can be safely managed without routine invasive endomyocardial biopsy (EMB)., Methods: The Invasive Monitoring Attenuation Through Gene Expression (IMAGE) study is a prospective, multicenter, non-blinded, randomized clinical trial designed to test the hypothesis that a primarily non-invasive rejection surveillance strategy utilizing GEP testing is not inferior to an invasive EMB-based strategy with respect to cardiac allograft dysfunction, rejection with hemodynamic compromise (HDC) and all-cause mortality., Results: A total of 199 heart transplant recipients in their second through fifth post-transplant years have been enrolled in the IMAGE study since January 13, 2005. The study is expected to continue through 2008., Conclusions: The IMAGE study is the first randomized, controlled comparison of two rejection surveillance strategies measuring outcomes in heart transplant recipients who are beyond their first year post-transplant. The move away from routine histologic evaluation for allograft rejection represents an important paradigm shift in cardiac transplantation, and the results of this study have important implications for the future management of heart transplant patients.
- Published
- 2007
- Full Text
- View/download PDF
38. Effect of reversible pulmonary hypertension on outcomes after heart transplantation.
- Author
-
Drakos SG, Kfoury AG, Gilbert EM, Horne BD, Long JW, Stringham JC, Campbell BA, and Renlund DG
- Subjects
- Administration, Sublingual, Adult, Female, Humans, Hypertension, Pulmonary physiopathology, Injections, Intravenous, Male, Middle Aged, Proportional Hazards Models, Retrospective Studies, Treatment Outcome, Vascular Resistance, Vasodilator Agents administration & dosage, Heart Diseases complications, Heart Diseases surgery, Heart Transplantation adverse effects, Heart Transplantation mortality, Hypertension, Pulmonary complications, Hypertension, Pulmonary drug therapy, Vasodilator Agents therapeutic use
- Abstract
Background: Conflicting data exist regarding the impact of reversible pulmonary hypertension (PHTN) on post-transplant (Tx) outcomes. In this study we sought to determine the influence of reversible PHTN on outcomes after Tx., Methods: We retrospectively reviewed the records of adult patients who underwent heart Tx from 1993 to 2002. Patients were grouped depending on their measured pulmonary vascular resistance (PVR). Group 1 patients had a pre-Tx pulmonary vascular resistance (PVR) of < 3 Wood units (WU). Patients with reversible PHTN, defined as pre-Tx PVR > or = 3 WU and reversing to < 3 WU either with sub-lingual or intravenous vasodilatory agents, were divided into two groups based on their PVR before the reversibility test (PVR: Group 2, 3 to 4.5 WU; Group 3, > 4.5 WU)., Results: Records for 222 adult heart recipients were reviewed (Group 1, n = 171; Group 2, n = 35; Group 3, n = 16). Baseline clinical characteristics (age, gender, heart failure etiology, history of diabetes, ischemic time, donor age and gender) were similar in the three groups and the average follow-up was 58 months. One-month and 1-year mortality (Groups 1, 2 and 3: 2%, 0% and 13%; and 8%, 0% and 13%, respectively) did not differ significantly between groups. Actuarial mortality was assessed using Cox regression analysis, adjusted for age and gender, and no increased risk of death was demonstrated for patients with reversible PHTN (for Group 2: multivariate hazard ratio [HR] 0.45, 95% confidence interval [CI] 0.17 to 1.32, p = 0.15; for Group 3: HR 0.98, CI 0.34 to 2.84, p = 0.97). No differences were observed between the three groups for various post-Tx events, such as hospital stay, ICU stay, extubation time, transfusions, acute allograft dysfunction, acute hepatic dysfunction, acute and chronic renal dysfunction, infections, neurologic complications, gastrointestinal complications and coronary allograft vasculopathy., Conclusions: Reversible pulmonary hypertension is associated with similarly good post-transplant survival outcomes and morbidity, regardless of severity.
- Published
- 2007
- Full Text
- View/download PDF
39. Multivariate predictors of heart transplantation outcomes in the era of chronic mechanical circulatory support.
- Author
-
Drakos SG, Kfoury AG, Gilbert EM, Long JW, Stringham JC, Hammond EH, Jones KW, Bull DA, Hagan ME, Folsom JW, Horne BD, and Renlund DG
- Subjects
- Adult, Female, Humans, Male, Middle Aged, Multivariate Analysis, Retrospective Studies, Assisted Circulation, Heart Transplantation adverse effects, Kidney Failure, Chronic etiology
- Abstract
Background: Determining which pretransplantation (TX) characteristics predict the development of chronic renal dysfunction (CRD) or death after heart TX would enable more accurate risk assessment at the time of candidate evaluation., Methods: A cohort of 278 patients underwent TX in three hospitals between 1993 and 2002. Predictive models for CRD (serum creatinine consistently above 2 mg/dL) and allograft loss (death or re-TX) were constructed using logistic and Cox regression, respectively., Results: Using logistic regression, CRD was more likely to develop in TX patients if they had a larger body surface area (odds ratio [OR] = 5.8 per m2, 95% confidence interval [CI] = 1.04 to 31.9, p = 0.04) or were inotrope dependent (OR = 1.8, 95% CI = 0.90 to 3.7, p = 0.09). Notably, the implementation of mechanical circulatory support as bridge to transplantation decreased the risk of CRD (OR = 0.30, 95% CI = 0.12 to 0.72, p = 0.007). Cox analysis demonstrated independent predictive ability of improved survival for males (hazard ratio [HR] = 0.42, 95% CI = 0.21 to 0.83, p = 0.01). Worse survival was observed with prior sternotomy (HR = 3.5, 95% CI = 2.0 to 6.0, p < 0.001), diabetes mellitus (HR = 1.9, 95% CI = 0.98 to 3.9, p = 0.06), and elevated serum creatinine (HR = 2.8 per mg/dL, 95% CI = 1.3 to 5.8, p = 0.007)., Conclusions: Certain pretransplant characteristics clearly predispose a patient to the development of CRD or increased mortality after heart transplantation. Interestingly, the risk of CRD after heart transplantation is greater for patients bridged to transplant with inotropes than with mechanical circulatory support. When hemodynamically indicated, timely implementation of pretransplant mechanical circulatory support should be considered.
- Published
- 2007
- Full Text
- View/download PDF
40. Impact of repetitive episodes of antibody-mediated or cellular rejection on cardiovascular mortality in cardiac transplant recipients: defining rejection patterns.
- Author
-
Kfoury AG, Stehlik J, Renlund DG, Snow G, Seaman JT, Gilbert EM, Stringham JS, Long JW, and Hammond ME
- Subjects
- Adult, Biopsy methods, Endpoint Determination, Female, Graft Rejection etiology, Heart Transplantation adverse effects, Heart Transplantation immunology, Humans, Immunosuppression Therapy methods, Kaplan-Meier Estimate, Male, Middle Aged, Prognosis, Retrospective Studies, Transplantation pathology, Transplantation, Homologous immunology, Transplantation, Homologous pathology, Treatment Outcome, Graft Rejection immunology, Graft Rejection pathology, Heart Transplantation mortality, Transplantation mortality
- Abstract
Background: In our previously published work dealing with antibody-mediated (vascular) rejection (AMR), we defined patterns of rejection (AMR and cellular rejection [CR]) based on a review of biopsy diagnoses taken in the first 6 to 12 weeks post-transplant. We have shown the significance of these pattern designations in relation to patient and allograft outcome in five outcome analyses. The current retrospective analysis was done to determine whether our previous criteria for pattern designations provided the greatest degree of discrimination between AMR and CR., Methods: Six hundred sixty-five patients from the U.T.A.H. Cardiac Transplant Program were included in our study. Patients induced with OKT3 immunosuppression were excluded. We analyzed the relationship of a number of either AMR or CR episodes to cardiovascular mortality. We constructed Kaplan-Meier survival curves to assess the impact of incremental numbers of AMR or CR episodes on cardiovascular mortality., Results: Three or more episodes of AMR resulted in a statistically significant increase in cardiovascular mortality. By contrast, CR episodes did not increase the risk of cardiovascular mortality., Conclusions: Based on our findings, we believe that clinical trials should be designed to test treatments based on predominant rejection patterns and that end-points for trials should be defined by number of biopsies positive for either CR or AMR. This approach may lead to improved patient and allograft survival.
- Published
- 2006
- Full Text
- View/download PDF
41. Low-dose prophylactic intravenous immunoglobulin does not prevent HLA sensitization in left ventricular assist device recipients.
- Author
-
Drakos SG, Kfoury AG, Long JW, Stringham JC, Fuller TC, Nelson KE, Campbell BK, Gilbert EM, and Renlund DG
- Subjects
- Adult, Female, Graft Rejection immunology, Graft Rejection prevention & control, Heart Transplantation immunology, Humans, Immunoglobulins, Intravenous administration & dosage, Immunosuppressive Agents administration & dosage, Male, Middle Aged, Pulsatile Flow, Retrospective Studies, Surface Properties, Treatment Failure, HLA Antigens immunology, Heart-Assist Devices adverse effects, Immunization, Immunoglobulins, Intravenous therapeutic use, Immunosuppressive Agents therapeutic use
- Abstract
Background: The use of left ventricular assist devices is associated with human leukocyte antigen (HLA) allosensitization. We investigated whether prophylactic treatment with low-dose intravenous immunoglobulin (IVIG), analogous to the use of IgG anti-D (anti-Rh) in preventing Rh immunization, can abrogate HLA allosensitization after left ventricular assist device implantation., Methods: We retrospectively reviewed the data from 84 consecutive heart failure patients who underwent implantation of a left ventricular assist device as a bridge to transplantation. After implantation, panel reactive antibody (PRA) was measured biweekly to assess sensitization (defined by PRA > 10%). Patients who were sensitized before left ventricular assist device implantation were excluded from further analysis (n = 12). Patients who either did not require perioperatively transfusions of cellular blood products or received other immunomodifying regimens were also excluded from further analysis (n = 21). The rest of the patients were divided into two groups based on whether they received IVIG, 10 g daily for 3 days (IVIG group, n = 26; non-IVIG group, n = 25). The decision as to whether patients received IVIG was not randomized but was based on surgeon preference., Results: The sensitization rates (expressed as ratio of sensitized patients to total patients at risk) in the two groups were similar at consecutive time points (2, 4, 6, 8, 12, 20 weeks) after left ventricular assist device implantation. Also, mean PRA at the same time points did not differ between the two groups. Overall, 34.6% (9 of 26) of the IVIG group became sensitized during mechanical support, compared with 32% (8 of 25) of the non-IVIG group (p = 1.0). A PRA of 90% or greater (high-degree sensitization) occurred in 15.3% (4 of 26) of the IVIG group and 12.0% (3 of 25) of the non-IVIG group (p = 0.5)., Conclusions: The use of low-dose prophylactic IVIG after left ventricular assist device implantation affects neither the incidence nor the severity of HLA allosensitization.
- Published
- 2006
- Full Text
- View/download PDF
42. Percutaneous coronary interventions with stents in cardiac transplant recipients.
- Author
-
Bader FM, Kfoury AG, Gilbert EM, Barry WH, Humayun N, Hagan ME, Thomas H, and Renlund D
- Subjects
- Coronary Restenosis prevention & control, Cytomegalovirus Infections immunology, Female, Follow-Up Studies, Humans, Male, Reoperation, Retrospective Studies, Sirolimus therapeutic use, Angioplasty, Balloon, Coronary, Coronary Artery Disease therapy, Heart Transplantation, Stents
- Abstract
Background: Allograft coronary vasculopathy is a major cause of death beyond the first year after cardiac transplantation. The aim of this study was to review our experience with percutaneous coronary intervention (PCI) with stents in cardiac transplant recipients., Methods: We identified patients who were treated with PCI using stents. Patient characteristics, procedure information and clinical outcomes were assessed for these patients by review of their medical records. We also compared results for those who had bare metal stents vs those who had drug-eluting stents., Results: Forty patients from our program's 865 cardiac transplant recipients received a total of 78 coronary stents. There were 35 males (87.5%) and 5 females (12.5%). The indication for PCI was progressive asymptomatic coronary vasculopathy in 18 patients (45%), angina in 5 (12.5%), acute myocardial infarction (MI) in 4 (10%) and congestive heart failure (CHF) in 6 (15%). Primary success (<50% residual stenosis) was obtained in 71 (91%) of 78 stents. During the mean follow-up of 40.8 +/- 34.5 months, 6 patients died (15%) and 2 (5%) were re-transplanted. There was a lower rate of re-stenosis with drug-eluting stents (2 of 13, 15%) compared with bare metal stents (20 of 65, 31%), although this difference was not statistically significant (p = 0.27)., Conclusions: In cardiac transplant recipients, PCI with stents can be performed with high rates of primary success. Restenosis rates are higher compared with PCI in native coronary arteries. A trend toward less restenosis with drug-eluting stents was observed, which needs to be confirmed in larger studies.
- Published
- 2006
- Full Text
- View/download PDF
43. Tricuspid valve replacement after cardiac transplantation.
- Author
-
Alharethi R, Bader F, Kfoury AG, Hammond ME, Karwande SV, Gilbert EM, Doty DB, Hagan ME, Thomas H, and Renlund DG
- Subjects
- Adult, Aged, Disease Progression, Female, Humans, Male, Middle Aged, Retrospective Studies, Risk Factors, Tricuspid Valve Insufficiency physiopathology, Heart Transplantation, Heart Valve Prosthesis Implantation, Postoperative Complications surgery, Tricuspid Valve Insufficiency surgery
- Abstract
Background: Tricuspid valve insufficiency (TI) is common after orthotopic heart transplantation. However, tricuspid valve replacement or repair (TVR) is rare. The aim of this study is to evaluate our experience with TVR in cardiac transplant recipients., Methods: The Utah Transplantation Affiliated Hospitals (UTAH) Cardiac Transplant Program database was queried for TVR in all adult and pediatric heart transplant recipients. Pre-operative parameters and cardiac hemodynamics were compared with post-operative findings., Results: Since 1985, we identified in our database 17 patients who had 16 TVR, and 2 tricuspid valve repair procedures. Thirty-four heart transplant recipients from the same period were used as controls. The indication for TVR was symptomatic right heart failure (RHF) in 89% of cases, and there was no significant difference between the control group and the surgery group in the average number of biopsies. A flail leaflet was found in 16 cases (89%). One patient died post-operatively due to cardiogenic shock, and 1 patient died 8 months after TVR due to progressive RHF. Improvement in heart failure symptoms was seen in 12 cases. The central venous pressure (CVP) decreased from 17.8 +/- 4.1 mm Hg to 11.0 +/- 7.3 mm Hg (p = 0.013). There was no significant change in cardiac output or renal function. However, the furosemide dose decreased significantly from 47.69 +/- 56.44 mg/day to 26.54 +/- 46.43 mg/day (p = 0.009)., Conclusions: After orthotopic heart transplantation, TVR is a safe and effective procedure to alleviate RHF symptoms. Flail leaflets are the most common operative finding, suggesting that biopsy-induced trauma is the likely cause of severe TI in these patients.
- Published
- 2006
- Full Text
- View/download PDF
44. Effect of mechanical circulatory support on outcomes after heart transplantation.
- Author
-
Drakos SG, Kfoury AG, Long JW, Stringham JC, Gilbert EM, Moore SA, Campbell BK, Nelson KE, Horne BD, and Renlund DG
- Subjects
- Acute Disease, Adult, Case-Control Studies, Chronic Disease, Female, Heart Failure surgery, Humans, Male, Middle Aged, Prognosis, Retrospective Studies, Risk Factors, Treatment Outcome, Heart Transplantation, Heart-Assist Devices
- Abstract
Background: Mechanical circulatory support (MCS) before heart transplantation was previously associated with worse post-transplant outcomes than when MCS was not required. Given the changes in technology, expertise, patient selection, and timing of subsequent transplantation, we hypothesized that patients who require MCS before heart transplantation have similar outcomes after transplantation as those not requiring pre-transplant MCS., Methods: We retrospectively reviewed 278 patients who underwent cardiac transplantation from 1993 to 2002. MCS was required in 72 patients (HeartMate LVAS in 66, CardioWest Total Artificial Heart in 6) and was not required in 206 patients. The influence of pre-transplant MCS on post-transplant outcomes was assessed in the 2 groups., Results: Baseline clinical characteristics (age, gender, etiology of heart failure, history of diabetes mellitus, and donor age and gender) were similar in the 2 groups. One-month and 1-year survival after transplantation did not differ between the groups (MCS, 92% and 85%, respectively vs no MCS, 97% and 92%, respectively). Similar proportions of patients were free from rejection (International Society for Heart and Lung Transplantation score >or=3A) at 1 year of follow-up (MCS, 56% vs no MCS, 52%, p = 0.60). No difference was observed between MCS and no MCS patients in other post-transplant events such as hospital stay, intensive care unit stay, extubation time, acute allograft dysfunction, reoperation rates, acute renal dysfunction, acute hepatic dysfunction, infections, arrhythmias, thromboembolic complications, neurologic complications, gastrointestinal complications and the development of cardiac allograft vasculopathy. The incidence of chronic renal insufficiency was actually lower in the MCS Group (15.3% vs 37.9%, p = .001)., Conclusion: Post-transplant outcomes after pre-transplant use of MCS are similar to those when MCS is not required.
- Published
- 2006
- Full Text
- View/download PDF
45. Utility of histologic parameters in screening for antibody-mediated rejection of the cardiac allograft: a study of 3,170 biopsies.
- Author
-
Hammond ME, Stehlik J, Snow G, Renlund DG, Seaman J, Dabbas B, Gilbert EM, Stringham JC, Long JW, and Kfoury AG
- Subjects
- Biopsy, Capillaries cytology, Cell Adhesion, Databases, Factual, Endothelium, Vascular pathology, Fluorescent Antibody Technique, Humans, Immunohistochemistry, Macrophages, Mass Screening, Predictive Value of Tests, Prospective Studies, Sensitivity and Specificity, Antibody Formation, Capillaries pathology, Graft Rejection immunology, Heart Transplantation immunology
- Abstract
Background: Diagnostic criteria for antibody-mediated rejection (AMR) of the cardiac allograft have recently been proposed as part of the International Society for Heart and Lung Transplantation (ISHLT) biopsy grading scheme. Histologic features of vascular adherence of macrophages (VASC) and endothelial activation or swelling in capillaries (ENDO) are proposed as criteria to prompt the immunohistochemical investigation of biopsies for AMR. The aim of this study was to determine whether VASC and ENDO are adequate to act as screening parameters to trigger further AMR investigation., Methods: We examined our database of biopsy findings where histologic vascular parameters as well as immunofluorescence (IF) to detect AMR were collected (n = 3,170). Histologic parameters were graded semi-quantitatively on a scale from 1 to 5, where 1 = absence and 5 = obvious and generalized presence of the finding., Results: Seven hundred sixty-eight of 3,170 biopsies had IF findings diagnostic of AMR in the absence of cellular rejection (ISHLT = 0). ENDO had a sensitivity of 63% and a specificity of 80%. VASC had a sensitivity of 30% and specificity of 99%. Combining the interpretation of the 2 tests did not result in a significant improvement of test sensitivity., Conclusions: Neither ENDO, VASC nor the combination of the tests indicated sufficiently high sensitivity to serve as a screening tool before further diagnostic investigation for AMR. Immunohistochemical testing remains necessary in the majority of cases to identify AMR.
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.